Thursday, after-hours Dexcom Inc (NASDAQ:DXCM) reported fourth-quarter 2023 earnings with sales of $1.03 billion, up 27% Y/Y (+26% on an organic basis), almost in line with the consensus estimate of $1.02 billion.
Volume growth, in conjunction with strong new customer additions, continues to be the primary driver of revenue growth as awareness of real-time continuous glucose monitoring increases.
The continuous glucose monitor maker posted profits of $256.3 million, almost triple the $91.8 million a year ago.
Adjusted EPS reached $0.50, beating the consensus of $0.43 and up from $0.34 a year ago.
Adjusted gross profit totaled $663.8 million or a margin of 64.2% compared to $543.7 million or 66.7% a year ago.
Adjusted operating income reached $242.7 million, compared to non-GAAP operating income of $172.1 million for the ...